Veracyte: Brent Shafer, Tom Miller
Veracyte has appointed Brent Shafer and Tom Miller to its board of directors, effective immediately. Shafer previously served as chairman and CEO of Cerner and CEO of Philips North America and Philips Home Healthcare Solutions. Before that, he served in a variety of roles at Hillrom, GE Medical Systems, and Johnson & Johnson. Miller is a scientist and entrepreneur with a focus on the combination of AI, chemistry, and biology. He is the cofounder and CEO of Iambic Therapeutics. Prior to that, he was a tenured professor at the California Institute of Technology.
Biofidelity: Kelly Ray Pitts, Catherine Jean Potgieter, Jonathan Senior
Genomic technology company Biofidelity has appointed Kelly Ray Pitts as chief operating officer, Catherine Jean Potgieter as VP of people, and Jonathan Senior as CFO.
Pitts was most recently COO at HepQuant. He has also previously held roles at Corgenix, C2N Diagnostics, Amgen, and Gilead, among other companies. He holds a Ph.D. in cell and molecular biology from Mayo Graduate School and a B.S. in biochemistry from Brigham Young University.
Potgieter has more than 20 years of human resources leadership experience including with companies such as Telensa, Sense Biodetection, and RealVNC. She is a graduate of the Chartered Institute of Personnel and Development and holds a postgraduate diploma in human resource management from Anglia Ruskin University.
Senior was most recently CFO of Sitryx Therapeutics and has served as a corporate financier and research analyst for several organizations. He holds a medical degree and a B.A. in physiological sciences from the University of Oxford.
Mobilion: Rohit Khanna
Mobilion has appointed Rohit Khanna to its board of directors. Khanna was most recently senior VP of applied technology at Waters. He was also cofounder of software engineering company Dynamic Solutions, which was acquired by Waters.
VedaBio: Brett Robb
Brett Robb has been appointed as senior scientific director and head of CRISPR science at VedaBio. Before joining the San Diego-based company, he spent almost 17 years at New England Biolabs, where he helped develop CRISPR-Cas reagents and RNA products. He holds a Ph.D. in medical biophysics from the University of Toronto and a B.S. in genetics from Western University.
Lifera Omics: Fowzan Alkuraya
Lifera Omics, a subsidiary of Lifera, has appointed Saudi human geneticist Fowzan Sami Alkuraya as its chief medical and genomics officer as well as a board member. Alkuraya previously served as the chairman of translational genomics at King Faisal Specialist Hospital and Research Centre and is currently a professor of human genetics at Alfaisal University.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.